eFfector Therapeutics reports Q3 EPS (13c), consensus (12c)

The company had cash, cash equivalents, and short-term investments totaling $17.8M as of September 30, compared to $25M as of June 30. The company anticipates that its current cash, cash equivalents and short-term investments will be sufficient to fund operations into the second quarter of 2024. “I am very pleased with the current position of the company, with two clinical programs approaching important data readouts,” said Steve Worland, president and chief executive officer of eFfector. “We now anticipate reporting topline results in our Phase 2b KICKSTART clinical trial of tomivosertib combined with pembrolizumab for the treatment of NSCLC in the first quarter of 2024. These results, if positive, would enable activities, including interactions with regulatory agencies, intended to support initiation of a Phase 3 registrational trial. Regarding our zotatifin program in ER+ mBC, we’re encouraged by the PFS data for the ZFA triplet, which is now mature, and anticipate providing a program update at the 2023 SABCS in December. We are now focusing on defining our registrational path for zotatifin in ER+ mBC and believe that the drug can be positioned as a second line therapy in multiple patient segments, with and without defined resistance mutations.”